CLOs on the Move

Consensus Orthopedics

www.consensusortho.com

 
Located in northern California, Consensus Orthopedics is committed to providing proven and reliable total joint implants and instruments to the global market. Consensus headquarters include administrative offices, research and design workrooms, manufacturing, inspection, clean room and warehouse space. With over 25 years of orthopedic design and manufacturing experience, together, through a focus on patient care and clinician relationships, Consensus is dedicated to creating one team, focused on restoring mobility and renewing lives.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Biowatch Medical Inc (Main)

Biowatch Medical Inc (Main) is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pearson Dental Supplies Co

Pearson Dental Supplies Co is a Sylmar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Industrial and Biomedical Sensors

Industrial & Biomedical Sensors Corp. is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lakeshore Biomaterials Inc

Lakeshore Biomaterials Inc is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.